SAN MATEO, Calif., July 21, 2011 /PRNewswire/ — Merz Aesthetics today announced that the United States
(U.S.) Food and Drug Administration (FDA) has approved XEOMIN®
(incobotulinumtoxinA) for the temporary improvement in the appearance of
moderate to severe glabellar lines, or frown lines between the
eyebrows, in adult patients.
“The FDA approval of XEOMIN is a significant milestone for Merz
Aesthetics and a promising addition to our entire aesthetics franchise,”
said Dennis Condon, President and Chief Business Officer
of Merz Aesthetics, Inc. “We are confident that XEOMIN will provide
patients and physicians with a new option for improving the appearance
of glabellar lines.”
“XEOMIN is a promising new option for both patients and physicians
and we are encouraged by the response rates seen in the Phase III
clinical trials,” said Derek H. Jones, M.D., an investigator for the XEOMIN U.S. study, Clinical Associate Professor of Medicine at the University of California in Los Angeles, Calif., and Director of Skin Care and Laser Physicians in Beverly Hills, Calif.
The approval of XEOMIN is based on the results of two pivotal U.S.
clinical trials involving 16 investigational sites and included 547
healthy adult patients. In both studies, XEOMIN significantly improved
the appearance of glabellar lines 30 days following the first injection,
when compared to placebo. XEOMIN is the only botulinum toxin currently
approved in the U.S. that does not require refrigeration prior to
reconstitution.
XEOMIN is approved for the temporary improvement in the appearance of
glabellar lines in 14 countries in the European Union (EU), including Germany, the United Kingdom, France, Italy and Spain, under the brand name BOCOUTURE®.
XEOMIN will be available nationwide to physicians in the spring of 2012.
To view the full release, please visit:
